Want to see TSE:ATLE full AI Analyst Report?
Willow Biosciences Inc (ATLE) AI Stock Analysis
Willow Biosciences Inc
(TSXV:ATLE)
Willow Biosciences receives a below-average score driven primarily by severe financial instability and profitability challenges (40% weight). The company's negative equity, persistent operating losses, and negative cash flow create material solvency risk that outweighs strong revenue growth. Technical analysis (30% weight) shows overbought conditions despite recent price strength, adding near-term downside risk. Valuation (30% weight) is difficult to assess due to unprofitability, but the negative P/E and deteriorating balance sheet suggest limited upside justification at current levels. While the 298% revenue growth demonstrates business traction, the company must demonstrate a clear path to profitability and stabilize its balance sheet to reduce investment risk materially.
Willow Biosciences Inc (ATLE) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 41.96M
- Dividend Yield
- ―
- Average Volume (3M)
- 82.88K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.34
- Revenue Growth
- -100.00%
- EPS Growth
- 94.43%
- Country
- Canada
- Employees
- 19
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Willow Biosciences Inc Business Overview & Revenue Model
Company Description
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and...
How the Company Makes Money
null
Willow Biosciences Inc Financial Statement Overview
Summary
Willow Biosciences demonstrates strong revenue growth (298% YoY to $4.66M) and improved gross margins (70.3%), but remains deeply unprofitable with a net margin of -132.8%. The balance sheet is severely compromised with negative stockholders' equity (-$0.5M) and negative equity ratio (-20.3%), indicating solvency risks. Cash flow remains substantially negative despite modest improvement. While top-line momentum is encouraging, the company's inability to achieve profitability combined with deteriorating financial stability presents material risk.
Income Statement
40NegativeBalance Sheet
15Very NegativeCash Flow
22NegativeWillow Biosciences Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ATLE, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 30.75 is Neutral, neither overbought nor oversold. The STOCH value of 19.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ATLE.
Willow Biosciences Inc Peers Comparison
Overall Rating
TSE:DB52Neutral
TSE:VEXT49Neutral- TSE:ATLE42Neutral
TSE:BNXT41Neutral
TSE:IAN41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:DB | 52Neutral | CAD 69.31M | -112.50 | -1.06% | ― | 26.44% | -104.43% |
| TSE:VEXT | 49Neutral | CAD 60.69M | -2.49 | -25.01% | ― | 13.60% | 11.06% |
| TSE:ATLE | 42Neutral | CAD 41.96M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
| TSE:BNXT | 41Neutral | CAD 35.38M | -3.52 | 117.02% | ― | ― | ― |
| TSE:IAN | 41Neutral | CAD 34.87M | -0.49 | 50.32% | ― | -11.58% | -1950.00% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:ATLE | Willow Biosciences | 0.09 | -0.07 | -43.75% | |
| TSE:IAN | Ianthus Capital Holdings (OTC) | 0.01 | 0.00 | 0.00% | |
| TSE:DB | Decibel Cannabis Company Inc | 1.80 | -0.30 | -14.29% | |
| TSE:VEXT | Vext Science | 0.24 | -0.03 | -9.26% | |
| TSE:BNXT | Bionxt Solutions Inc | 0.26 | -0.57 | -68.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 07, 2025